1
|
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. Drugs 2021; 82:15-32. [PMID: 34894338 DOI: 10.1007/s40265-021-01654-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/22/2021] [Indexed: 12/20/2022]
Abstract
In oncology, and especially in the treatment of non-small-cell lung cancer (NSCLC), dose optimization is often a neglected part of precision medicine. Many drugs are still being administered in "one dose fits all" regimens or based on parameters that are often only minor determinants for systemic exposure. These dosing approaches often introduce additional pharmacokinetic variability and do not add to treatment outcomes. Fortunately, pharmacological knowledge is increasing, providing valuable information regarding the potential of, for example, therapeutic drug monitoring. This article focuses on the evidence for the most promising and easily implemented optimized dosing approaches for the small-molecule inhibitors, chemotherapeutic agents, and monoclonal antibodies as treatment options currently approved for NSCLC. Despite limitations such as investigations having been conducted in oncological diseases other than NSCLC or the retrospective origin of many analyses, an alternative dosing regimen could be beneficial for treatment outcomes, prescriber convenience, or financial burden on healthcare systems. This review of the literature provides recommendations on the implementation of dose optimization and advice regarding promising strategies that deserve further research in NSCLC.
Collapse
|
2
|
Ishida S, Makihara Y, Watanabe H, Nakashima T, Nagata K, Suetsugu K, Tsuji T, Hata K, Ikeda M, Ikebe M, Minami H, Watanabe H, Nakata K, Nakamura M, Egashira N, Ieiri I. Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer. Ann Pharmacother 2020; 55:738-744. [PMID: 33094647 DOI: 10.1177/1060028020969354] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Peripheral intravenous injection of gemcitabine often causes vascular pain; however, preventive measures have not yet been established. OBJECTIVES This study focused on identifying predictive factors for gemcitabine-induced vascular pain. METHODS We retrospectively analyzed risk factors for developing vascular pain in patients with pancreatic cancer receiving gemcitabine infusions at our institution. Infusions were divided into groups according to presence or absence of vascular pain symptoms, and variables were compared. Odds ratios for risk factors were calculated using logistic regression analyses. RESULTS Overall, 272 patients with pancreatic cancer were subjected to 725 gemcitabine infusions, and of these, 18.4% (n = 50) experienced vascular pain. There were significant differences in the gemcitabine dose (P = 0.025), dose of gemcitabine/body surface area (BSA; P = 0.004), concentration of gemcitabine (P = 0.025), and hot pack use (P = 0.011) between the vascular pain and no vascular pain groups. Multivariable analyses indicated that gemcitabine dose/BSA and lack of hot pack use were risk factors for developing vascular pain. Moreover, on administration of a higher dosage (>930 mg/m2), the incidence of vascular pain in patients using a hot pack (6.7%) was significantly lower than that in patients not provided a hot pack (16.2%). CONCLUSIONS AND RELEVANCE High gemcitabine dosages and lack of hot pack use were predictive factors for gemcitabine-induced vascular pain in patients with pancreatic cancer. Patients receiving gemcitabine treatment should apply a hot pack to the injection site. Scrupulous clinical attention is required for patients presenting with these risk factors to improve pain management.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Mio Ikebe
- Kyushu University Hospital, Fukuoka, Japan
| | | | | | | | | | | | | |
Collapse
|
3
|
Dehua Z, Mingming C, Jisheng W. Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer. PLoS One 2018; 13:e0193814. [PMID: 29561887 PMCID: PMC5862432 DOI: 10.1371/journal.pone.0193814] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 02/19/2018] [Indexed: 11/25/2022] Open
Abstract
Objective To evaluate the efficacy and safety of gemcitabine (GEM) at 30 min standard-dose infusion (30 min-SDI) compared with prolonged low-dose infusion (P-LDI) in patients with advanced non-small-cell lung cancer (NSCLC). Methods Electronic databases including Pubmed, EMbase, Cochrane Library, CNKI, CBM, and VIP were searched using keywords “GEM”, “P-LDI”, and “NSCLC”. Review Manager 5.3 was used to perform the meta-analysis. Primary endpoints were overall response rate (ORR) and 1-year survival rate (1-year SR). Secondary endpoints were grade 3/4 hematotoxicity and nausea/vomiting. In association. GRADE quality of evidence system was used to assess the results of meta-analysis. Results Six randomized controlled trials (RCTs) with a total of 637 patients were included and no statistical heterogeneity was found among the studies. The results showed that P-LDI was superior in ORR (RD = 0.09, 95% CI: 0.02 to 0.16, P = 0.02), but had a similar 1-year SR (RD = 0.05, 95% CI: -0.02 to 0.12, P = 0.18) as compared with 30 min-SDI. For grade 3/4 adverse events, there was no significant difference in anemia (RD = 0.02, 95% CI: -0.01 to 0.04, P = 0.27) and nausea/vomiting (RD = 0.01, 95% CI: -0.04 to 0.06, P = 0.64) between the two treatments. However, patients with P-LDI experienced less leukopenia (RD = -0.08, 95% CI: -0.15 to -0.01, P = 0.03) and thrombocytopenia ((RD = -0.05, 95% CI: -0.09 to –0.01, P = 0.006). The GRADE profile showed that the included RCTs had low quality of evidences. Conclusion P-LDI was superior in terms of ORR, experienced less grade 3/4 thrombocytopenia and leukopenia compared with 30 min-SDI, and could be a viable treatment option for advanced NSCLC. However, the results need to be further verified by high quality trials and large samples owing to the low quality of evidences.
Collapse
Affiliation(s)
- Zhao Dehua
- Dept. of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang, Sichuan, China
| | - Chu Mingming
- Dept. of Clinical Pharmacy, The Second Affiliated Hospital of Third Military Medical University, Chongqing, China
| | - Wang Jisheng
- Dept. of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang, Sichuan, China
- * E-mail:
| |
Collapse
|
4
|
Nguyen HX, Do TNV, Le TH, Nguyen MTT, Nguyen NT, Esumi H, Awale S. Chemical Constituents of Mangifera indica and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line. JOURNAL OF NATURAL PRODUCTS 2016; 79:2053-2059. [PMID: 27466882 DOI: 10.1021/acs.jnatprod.6b00381] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Human pancreatic cancer cell lines such as PANC-1 have an altered metabolism, enabiling them to tolerate and survive under extreme conditions of nutrient starvation. The search for candidates that inhibit their viability during nutrition starvation represents a novel antiausterity strategy in anticancer drug discovery. A methanol extract of the bark of Mangifera indica was found to inhibit the survival of PANC-1 human pancreatic cancer cells preferentially under nutrient-deprived conditions with a PC50 value of 15.5 μg/mL, without apparent toxicity, in normal nutrient-rich conditions. Chemical investigation on this bioactive extract led to the isolation of 19 compounds (1-19), including two new cycloartane-type triterpenes, mangiferolate A (1) and mangiferolate B (2). The structures of 1 and 2 were determined by NMR spectroscopic analysis. Among the isolated compounds, mangiferolate B (2) and isoambolic acid (12) exhibited potent preferential cytotoxicity against PANC-1 human pancreatic cancer cells under the nutrition-deprived condition with PC50 values of 11.0 and 4.8 μM, respectively.
Collapse
Affiliation(s)
- Hai Xuan Nguyen
- Faculty of Chemistry, University of Science, Vietnam National University-Hochiminh City , 227 Nguyen Van Cu Street, District 5, Vietnam
| | - Truong Nhat Van Do
- Faculty of Chemistry, University of Science, Vietnam National University-Hochiminh City , 227 Nguyen Van Cu Street, District 5, Vietnam
| | - Tho Huu Le
- Faculty of Chemistry, University of Science, Vietnam National University-Hochiminh City , 227 Nguyen Van Cu Street, District 5, Vietnam
| | - Mai Thanh Thi Nguyen
- Faculty of Chemistry, University of Science, Vietnam National University-Hochiminh City , 227 Nguyen Van Cu Street, District 5, Vietnam
| | - Nhan Trung Nguyen
- Faculty of Chemistry, University of Science, Vietnam National University-Hochiminh City , 227 Nguyen Van Cu Street, District 5, Vietnam
| | - Hiroyasu Esumi
- Research Institute for Biomedical Sciences, Tokyo University of Science , Chiba 278-8510, Japan
| | - Suresh Awale
- Division of Natural Drug Discovery, Department of Translational Research, Institute of Natural Medicine, University of Toyama , 2630 Sugitani, Toyama 930-0194, Japan
| |
Collapse
|
5
|
Nguyen MTT, Nguyen NT, Awale S. Prenylated Dihydrochalcones from Artocarpus altilis as Antiausterity Agents. ACTA ACUST UNITED AC 2015; 37:95-110. [DOI: 10.1016/bs.enz.2015.05.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/20/2023]
|
6
|
Xie J, Yuan J, Lu L. Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials. Diagn Pathol 2014; 9:214. [PMID: 25421173 PMCID: PMC4251942 DOI: 10.1186/s13000-014-0214-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2014] [Accepted: 10/26/2014] [Indexed: 02/08/2023] Open
Abstract
Background Pre-clinical evidence shows that fixed dose rate (FDR) infusion of gemcitabine could optimize plasma concentration of gemcitabine, while the clinical efficacy and toxicity of FDR infusion of gemcitabine in advanced pancreatic carcinoma has not been systematically investigated. Thus, this meta-analysis was designed to ascertain this issue. Methods Databases of EMBASE, PubMed, and Cochrane Library were searched for eligible randomized controlled trials (RCTs). RCTs comparing FDR and standard 30-min infusion of gemcitabine in advanced pancreatic carcinoma were included. The primary endpoints were treatment efficacy (overall response rate, 1-year survival rate, median survival, and time to treatment failure) and toxicities were secondary endpoints (neutropenia, thrombocytopenia, anemia, and vomiting). Relative risks or mean differences and corresponding 95% confidence intervals (CIs) were calculated. Result After careful and rigorous selection, 3 eligible RCTs including 764 patients of advanced pancreatic adenocarcinoma were included in this meta-analysis. For treatment efficacy, FDR gemcitabine provided significantly longer median survival over standard gemcitabine (Mean Difference = 1.24 months, 95% CI: 0.39-2.09), while there was no statistical difference in other endpoints of treatment efficacy. For toxicities, patients with FDR gemcitabine experienced significantly more grade 3/4 hematological toxicities than those received standard gemcitabine (neutropenia, thrombocytopenia, and anemia), while there was no difference for vomiting. Conclusion Compared with standard 30-min infusion, FDR gemcitabine provide longer median survival, but increased the risk of hematological toxicities for patients with advanced pancreatic adenocarcinoma. Virtual Slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_214 Electronic supplementary material The online version of this article (doi:10.1186/s13000-014-0214-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jiqing Xie
- Department of Pharmacy, General Hospital of Jinan Military Command, Jinan, 250031, China.
| | - Jing Yuan
- Department of Medical Information, General Hospital of Jinan Military Command, Jinan, 250031, China.
| | - Laichun Lu
- Department of Pharmacy, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Changjiang Road 10, Chongqing, 400042, China.
| |
Collapse
|
7
|
Zhu C, Zhou GX. Inhibition of arachidonic acid metabolism to decrease pancreatic cancer cell proliferation. Shijie Huaren Xiaohua Zazhi 2014; 22:1106-1111. [DOI: 10.11569/wcjd.v22.i8.1106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the effect of inhibition of arachidonic acid metabolism on proliferation of pancreatic cancer cells.
METHODS: Cultured pancreatic cancer SW1990 cells were treated with different concentrations of MK886, celecoxib, or MK886 + celecoxib. After treatment, the expression of leukotriene B4 receptor 1 (BLT1) and vascular endothelial growth factor (VEGF) mRNAs was detected by semi-quantitative RT-PCR and the expression of phosphorylated extracellular regulated protein (p-Erk) was measured by Western blot.
RESULTS: Treatment with MK886 significantly decreased the expression of BLT1 and VEGF mRNAs (P < 0.01 for both) and p-Erk (P < 0.05). Treatment with celecoxib did not alter the expression of BLT1 mRNA and decreased the expression of VEGF mRNA compared with untreated cells (P < 0.01), but increased the expression of p-Erk compared with the MK886 group (P < 0.01). Treatment with MK886 and celecoxib significantly decreased the expression of BLT1 and VEGF mRNAs (P < 0.01 for both), but did not alter the expression of p-Erk.
CONCLUSION: Both two pathways of arachidonic acid metabolism are associated with pancreatic cancer cell proliferation, with the pathway involving 5-lipoxygenase being more important.
Collapse
|
8
|
Ueda JY, Athikomkulchai S, Miyatake R, Saiki I, Esumi H, Awale S. (+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death. DRUG DESIGN DEVELOPMENT AND THERAPY 2013; 8:39-47. [PMID: 24379655 PMCID: PMC3872082 DOI: 10.2147/dddt.s52168] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Human pancreatic tumors are known to be highly resistant to nutrient starvation, and this prolongs their survival in the hypovascular (austere) tumor microenvironment. Agents that retard this tolerance to nutrient starvation represent a novel antiausterity strategy in anticancer drug discovery. (+)-Grandifloracin (GF), isolated from Uvaria dac, has shown preferential toxicity to PANC-1 human pancreatic cancer cells under nutrient starvation, with a PC50 value of 14.5 μM. However, the underlying mechanism is not clear. In this study, GF was found to preferentially induce PANC-1 cell death in a nutrient-deprived medium via hyperactivation of autophagy, as evidenced by a dramatic upregulation of microtubule-associated protein 1 light chain 3. No change was observed in expression of the caspase-3 and Bcl-2 apoptosis marker proteins. GF was also found to strongly inhibit the activation of Akt, a key regulator of cancer cell survival and proliferation. Because pancreatic tumors are highly resistant to current therapies that induce apoptosis, the alternative cell death mechanism exhibited by GF provides a novel therapeutic insight into antiausterity drug candidates.
Collapse
Affiliation(s)
- Jun-ya Ueda
- Frontier Research Core for Life Sciences, Toyama, Japan ; Institute of Natural Medicine, University of Toyama, Toyama, Japan
| | | | - Ryuta Miyatake
- Graduate School of Science and Engineering, University of Toyama, Toyama, Japan
| | - Ikuo Saiki
- Institute of Natural Medicine, University of Toyama, Toyama, Japan
| | - Hiroyasu Esumi
- Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan ; National Cancer Center Hospital East, Chiba, Japan
| | - Suresh Awale
- Frontier Research Core for Life Sciences, Toyama, Japan ; Institute of Natural Medicine, University of Toyama, Toyama, Japan
| |
Collapse
|